Department of Cardiology, Solothurner Spitäler AG, Kantonsspital Olten, Olten, Switzerland.
Faculty of Medicine, University of Basel, Basel, Switzerland.
JMIR Res Protoc. 2024 May 31;13:e55953. doi: 10.2196/55953.
The results of telemedicine intervention studies in patients with heart failure (HF) to reduce rehospitalization rate and mortality by early detection of HF decompensation are encouraging. However, the benefits are lower than expected. A possible reason for this could be the fact that vital signs, including blood pressure, heart rate, heart rhythm, and weight changes, may not be ideal indicators of the early stages of HF decompensation but are more sensitive for acute events triggered by ischemic episodes or rhythm disturbances. Preliminary results indicate a potential role of ambient sensor-derived digital biomarkers in this setting.
The aim of this study is to identify changes in ambient sensor system-derived digital biomarkers with a high potential for early detection of HF decompensation.
This is a prospective interventional cohort study. A total of 24 consecutive patients with HF aged 70 years and older, living alone, and hospitalized for HF decompensation will be included. Physical activity in the apartment and toilet visits are quantified using a commercially available, passive, infrared motion sensing system (DomoHealth SA). Heart rate, respiration rate, and toss-and-turns in bed are recorded by using a commercially available Emfit QS device (Emfit Ltd), which is a contact-free piezoelectric sensor placed under the participant's mattress. Sensor data are visualized on a dedicated dashboard for easy monitoring by health professionals. Digital biomarkers are evaluated for predefined signs of HF decompensation, including particularly decreased physical activity; time spent in bed; increasing numbers of toilet visits at night; and increasing heart rate, respiration rate, and motion in bed at night. When predefined changes in digital biomarkers occur, patients will be called in for clinical evaluation, and N-terminal pro b-type natriuretic peptide measurement (an increase of >30% considered as significant) will be performed. The sensitivity and specificity of the different biomarkers and their combinations for the detection of HF decompensation will be calculated.
The study is in the data collection phase. Study recruitment started in February 2024. Data analysis is scheduled to start after all data are collected. As of manuscript submission, 5 patients have been recruited. Results are expected to be published by the end of 2025.
The results of this study will add to the current knowledge about opportunities for telemedicine to monitor older patients with HF living at home alone by evaluating the potential of ambient sensor systems for this purpose. Timely recognition of HF decompensation could enable proactive management, potentially reducing health care costs associated with preventable emergency presentations or hospitalizations.
ClinicalTrials.gov NCT06126848; https://clinicaltrials.gov/study/NCT06126848.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/55953.
远程医疗干预研究结果表明,通过早期检测心力衰竭(HF)代偿失调,可降低再住院率和死亡率。然而,其益处低于预期。造成这种情况的一个可能原因是,包括血压、心率、心律和体重变化在内的生命体征可能不是心力衰竭代偿失调早期阶段的理想指标,但对于由缺血发作或节律紊乱引发的急性事件更为敏感。初步结果表明,环境传感器衍生的数字生物标志物在这方面可能具有潜在作用。
本研究旨在确定环境传感器系统衍生的数字生物标志物变化,以早期检测心力衰竭代偿失调。
这是一项前瞻性干预性队列研究。共纳入 24 例年龄在 70 岁及以上、独居且因心力衰竭失代偿而住院的连续心力衰竭患者。使用商业上可获得的被动式红外线运动感应系统(DomoHealth SA)量化公寓内的身体活动和厕所使用情况。使用商业上可获得的无接触压电传感器 Emfit QS 设备(Emfit Ltd)记录心率、呼吸率和床上翻身次数,该传感器放置在参与者的床垫下。传感器数据在专用仪表板上可视化,以便卫生专业人员轻松监测。评估数字生物标志物是否存在心力衰竭失代偿的特定迹象,包括身体活动明显减少;卧床时间增加;夜间上厕所次数增加;夜间心率、呼吸率和床上运动增加。当数字生物标志物发生预设变化时,将通知患者进行临床评估,并进行 N-末端 pro-B 型利钠肽测量(增加>30%被认为有意义)。将计算不同生物标志物及其组合对心力衰竭失代偿检测的灵敏度和特异性。
该研究处于数据收集阶段。研究招募于 2024 年 2 月开始。计划在收集完所有数据后开始数据分析。截至提交稿件时,已有 5 名患者入组。预计结果将于 2025 年底公布。
该研究结果将通过评估环境传感器系统在这方面的潜力,为通过远程医疗监测独居在家的老年心力衰竭患者提供更多信息,补充当前关于远程医疗监测的知识。及时识别心力衰竭失代偿可能有助于主动管理,从而降低与可预防的紧急就诊或住院相关的医疗保健成本。
ClinicalTrials.gov NCT06126848;https://clinicaltrials.gov/study/NCT06126848。
国际注册报告标识符(IRRID):PRR1-10.2196/55953。